바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.71 No.4
Citation Share

Successful Rechallenge with Gefitinib for an Initial Erlotinib-Responder with Advanced Lung Adenocarcinoma

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2011, v.71 no.4, pp.286-290





& (2011). Successful Rechallenge with Gefitinib for an Initial Erlotinib-Responder with Advanced Lung Adenocarcinoma. Tuberculosis & Respiratory Diseases, 71(4), 286-290.
  • Downloaded
  • Viewed
PDF Download

Abstract

Although failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) is generally believed to be associated with cross-resistance to other EGFR TKI, the benefit of administering erlotinib as a second EGFR TKI after resistance of gefitinib as the first TKI has been well known. However, good response to gefitinib after an initial response to erlotinib has been rare. We report that a 45-year-old woman (never smoked), with lung adenocarcinoma and EGFR mutation, showed an initial response to erlotinib, and then responded to gefitinib again.

keywords
erlotinib, gefitinib, Adenocarcinoma of lung, erlotinib, gefitinib, Adenocarcinoma of lung

Reference

1.

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.

2.

2. Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, et al. Phase II study of erlotinib in advanced non-smallcell lung cancer after failure of gefitinib. J Clin Oncol 2007;25:2528-33.

3.

3. Wong AS, Soong R, Seah SB, Lim SW, Chuah KL, Nga ME, et al. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol 2008;3:400-4.

4.

4. Chang JW, Chou CL, Huang SF, Wang HM, Hsieh JJ, Hsu T, et al. Erlotinib response of EGFR-mutant gefitinib- resistant non-small-cell lung cancer. Lung Cancer 2007;58:414-7.

5.

5. Gridelli C, Maione P, Galetta D, Colantuoni G, Del Gaizo F, Ferrara C, et al. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. J Thorac Oncol 2007;2:758-61.

6.

6. Kim HK, Ahn MI, Yoo J, Kim CH, Yang HJ, Shim BY. Sequential responses of adenocarcinoma of the lung to erlotinib after gefitinib in never smoker Korean woman. Cancer Res Treat 2007;39:37-9.

7.

7. Wong AS, Seto KY, Chin TM, Soo RA. Lung cancer response to gefitinib, then erlotinib, then gefitinib again. J Thorac Oncol 2008;3:1077-8.

8.

8. Wu SG, Shih JY, Yu CJ, Yang PC. Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation. J Thorac Oncol 2008;3:451-2.

9.

9. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.

10.

10. Viswanathan A, Pillot G, Govindan R. Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2005;50:417-8.

11.

11. Fukui T, Otani S, Hataishi R, Jiang SX, Nishii Y, Igawa S, et al. Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemother Pharmacol 2010;65:803-6.

12.

12. Yokouchi H, Yamazaki K, Kinoshita I, Konishi J, Asahina H, Sukoh N, et al. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 2007;7: 51.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy